By contrast, broadly neutralizing Abs (bnAbs) emerge in about 50% of HIV-infected persons within two years of infection (Stamatatos et al., 2009, Hraber et al., 2014), and potent human monoclonal Abs (mAbs) of various epitope specificities that are capable of neutralizing > 90% of circulating HIV-1 strains have been generated from memory B cells of HIV-infected persons (Mascola and Haynes, 2013, Burton and Mascola, 2015, Walker et al., 2011, Falkowska et al., 2012, Wu et al., 2010). This evidence concerns the gene DDX41 and infection.